Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC)
(1) Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Although various serum enzymes have been utilized for the diagnosis and prognosis of HCC, the currently available biomarkers lack the sensitivity needed to detect HCC at early stages and ac...
Main Authors: | Taehee Lee, Piper A. Rawding, Jiyoon Bu, Sunghee Hyun, Woosun Rou, Hongjae Jeon, Seokhyun Kim, Byungseok Lee, Luke J. Kubiatowicz, Dawon Kim, Seungpyo Hong, Hyuksoo Eun |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/9/2061 |
Similar Items
-
Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation
by: Jonathan Dao, et al.
Published: (2023-08-01) -
Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care
by: Inah Marie C. Aquino, et al.
Published: (2024-03-01) -
Sensitive and Specific Analyses of Colorectal Cancer Recurrence through Multiplex superRCA Mutation Detection in Blood Plasma
by: Emma Sandberg, et al.
Published: (2024-01-01) -
Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood
by: Stine H. Kresse, et al.
Published: (2023-09-01) -
Can Liquid Biopsy Based on ctDNA/cfDNA Replace Tissue Biopsy for the Precision Treatment of EGFR-Mutated NSCLC?
by: Yi-Ze Li, et al.
Published: (2023-02-01)